Mild cognitive impairment exists in Parkinson's disease

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F11%3A00055888" target="_blank" >RIV/00216224:14110/11:00055888 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1007/s00702-011-0674-x" target="_blank" >http://dx.doi.org/10.1007/s00702-011-0674-x</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s00702-011-0674-x" target="_blank" >10.1007/s00702-011-0674-x</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Mild cognitive impairment exists in Parkinson's disease

Popis výsledku v původním jazyce

Cognitive impairment exists in Parkinsons disease (PD) as a transitional state between cognitively intact and demented PD patients. It seems to be a risk factor for the development of dementia in PD, but the precise criteria and unfavorable cognitive profile of mild cognitive impairment in PD (MCI-PD) have not yet been established. The concept may turn to be different from that in Alzheimers disease since we search for those already diagnosed PD patients who are at risk of developing dementia. In addition, clinical variables specific for PD also play role. Importantly, MCI possesses a metabolic basis in PD. Various biomarkers particularly including neuropsychological testing and the brain imaging hold promise in identification of MCI-PD patients with unfavorable prognoses. Well-designed longitudinal studies in MCI-PD cohorts are needed to assess the sensitivity and specificity of the PD-MCI designation as far as dementia development is concerned.

Název v anglickém jazyce

Mild cognitive impairment exists in Parkinson's disease

Popis výsledku anglicky

Cognitive impairment exists in Parkinsons disease (PD) as a transitional state between cognitively intact and demented PD patients. It seems to be a risk factor for the development of dementia in PD, but the precise criteria and unfavorable cognitive profile of mild cognitive impairment in PD (MCI-PD) have not yet been established. The concept may turn to be different from that in Alzheimers disease since we search for those already diagnosed PD patients who are at risk of developing dementia. In addition, clinical variables specific for PD also play role. Importantly, MCI possesses a metabolic basis in PD. Various biomarkers particularly including neuropsychological testing and the brain imaging hold promise in identification of MCI-PD patients with unfavorable prognoses. Well-designed longitudinal studies in MCI-PD cohorts are needed to assess the sensitivity and specificity of the PD-MCI designation as far as dementia development is concerned.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FH - Neurologie, neurochirurgie, neurovědy

OECD FORD obor

—

Projekt

—

Návaznosti

Z - Vyzkumny zamer (s odkazem do CEZ)

Rok uplatnění

2011

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Neural Transmission

ISSN

0300-9564

e-ISSN

—

Svazek periodika

118

Číslo periodika v rámci svazku

8

Stát vydavatele periodika

AT - Rakouská republika

Počet stran výsledku

5

Strana od-do

1179-1183

Kód UT WoS článku

000293244800008

EID výsledku v databázi Scopus

—